Additionally, expression of PD-L1 was positively correlated with HIF-1α, which may provide evidences for a novel combinational therapy targeting PD-L1 and HIF-1α in NSCLC patients. The gene discussed is HIF1A; the disease is non-small cell lung carcinoma.